FDA Approves Fresenius Kabi’s Tyenne, a Biosimilar of Actemra for the Treatment of Autoimmune Diseases

Medication is the first tocilizumab biosimilar approved in the US for both IV and subcutaneous use for autoimmune diseases, such as rheumatoid arthritis and juvenile idiopathic arthritis.

Source link
#FDA #Approves #Fresenius #Kabis #Tyenne #Biosimilar #Actemra #Treatment #Autoimmune #Diseases